Efanesoctocog Alfa
Severe Hemophilia A
Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Swedish Orphan Biovitrum
Modality
protein_peptide
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05817812CT.gov A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Severe Hemophilia A
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Efanesoctocog Alfa (this asset) | Swedish Orphan Biovitrum | P3 | BB · 64 |
| Human Antihemophilic Factor/Von Willebrand Factor Complex | AryoGen Pharmed Co. | P4 | BBB |
| Emicizumab | Chulalongkorn University | P4 | BBB |
| Human-Cl Rhfviii | Octapharma | P3 | BBB |
| Rfviiifc | Bioverativ Therapeutics Inc. | P3 | BB |
| Alphanate Sd/Ht | Grifols Biologicals, LLC | P4 | BB |
| Frsw117 | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | P3 | BB |
| Advate | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | P3 | BB |
| Lonoctocog Alfa | CSL Behring | P3 | B |
+13 more in the Severe Hemophilia A cohort
Other indications for Efanesoctocog Alfa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hemophilia A | — | P4 | BBB · 72 |
| Hemophilia | — | P4 | BB · 65 |
| Synovitis | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Efanesoctocog Alfa in Severe Hemophilia A. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/efanesoctocog-alfa-severe-hemophilia-a
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →